Cabozantinib in High Grade Neuroendocrine Neoplasms
Status:
Recruiting
Trial end date:
2024-11-30
Target enrollment:
Participant gender:
Summary
High grade neuroendocrine neoplasm patients are treated with platinum doublets such as
carboplatin and etoposide mimicking the current guidelines for small cell lung cancer (SCLC).
Unfortunately, recurrences are common and most patients with metastatic disease succumb to it
within a year. There is no extensive literature or consensus on second- or third-line options
(which include FOLFOX, FOLFIRI, capecitabine and temozolomide, taxanes or immunotherapy) and
there is urgent need for better regimens.